Allogene Therapeutics, Inc. Operating Lease Right-of-Use Assets
Allogene Therapeutics, Inc. (ALLO) had Operating Lease Right-of-Use Assets of $37.74 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-12
- 2026-06-30: Operating Lease, Right-of-Use Asset $37.74M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $38.82M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $39.89M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $40.94M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $37.74M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $38.82M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $39.89M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $40.94M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $41.97M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $44.08M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $45.20M 10-K · filed 2026-03-12 |
| 2024-09-30 | $46.31M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $58.38M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $64.48M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $63.70M 10-K · filed 2025-03-13 |
| 2023-09-30 | $78.64M 10-K · filed 2024-03-14 |
| 2023-06-30 | $80.31M 10-K · filed 2024-03-14 |
| 2023-03-31 | $81.96M 10-K · filed 2024-03-14 |
| 2022-12-31 | $83.59M 10-K/A · filed 2024-03-14 |
| 2022-09-30 | $85.25M 10-K · filed 2024-03-14 |
| 2022-06-30 | $86.84M 10-K · filed 2024-03-14 |
| 2022-03-31 | $57.06M 10-K · filed 2024-03-14 |
| 2021-12-31 | $58.03M 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $38.76M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $39.47M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $40.19M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $41.30M 10-K · filed 2022-02-23 |
| 2020-09-30 | $41.56M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $42.43M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $43.84M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $44.49M 10-K · filed 2021-02-25 |
| 2019-09-30 | $31.44M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $31.88M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $32.39M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $33.02M 10-K · filed 2020-02-27 |
| 2018-09-30 | $25.00M 10-Q · filed 2018-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |